David Mahvi to Antibodies, Monoclonal
This is a "connection" page, showing publications David Mahvi has written about Antibodies, Monoclonal.
Connection Strength
0.376
-
Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma. Cancer Immunol Immunother. 2018 Oct; 67(10):1647-1658.
Score: 0.124
-
Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma. Clin Cancer Res. 2009 Aug 01; 15(15):4875-84.
Score: 0.066
-
Carcinoma of the pancreas. Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody. Ann Surg. 1985 Oct; 202(4):440-5.
Score: 0.051
-
Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma. Cancer Immunol Immunother. 2006 Jul; 55(7):761-74.
Score: 0.051
-
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol. 2004 Nov 15; 22(22):4463-73.
Score: 0.048
-
Screening for occult nodal metastasis in squamous cell carcinoma of the vulva. Int J Gynecol Pathol. 2000 Jul; 19(3):243-7.
Score: 0.035